Views
4 years ago

90 - MS Gonçalves Borrega - Febrero 2015

  • Text
  • Borrega
  • Schizophrenia
  • Psychosis
  • Psicosis
  • Esquizofrenia
  • Psico
  • Endocannabinoide
  • Gaba
  • Comt
  • Alteraciones
  • Actividad
  • Consumo
  • Receptor
  • Sistema
  • Receptores
  • Cannabis
Consumo de cannabis durante la adolescencia

Dra. María Silvana

Dra. María Silvana Gonçalves Borrega cannabinoid receptor at excitatory presynaptic sites in the hippocampus and cerebellum”, Journal of Neuroscience, 2006, 26:2991–3001. Laruelle M., Abi-Dargham A, Van Dyck C.H., Gil R., D’Souza C.D., Redos J., McCance E., Rosenblatt W., Fingado C., Zoghbi S.S., Baldwin R.M., Seibyl J.P., Krystal J.H., Charney D.S. e Innis R.B., “Single photon emission computarizaed tomography imaging of amphetamine-induced dopamine release in drug free schizophrenic subjects”, Proc Natl Acad Sci USA, 1996, 93: 9235-9240 Laviolette S.R. y Grace A.A.” Cannabinoids potentiate emotional learning plasticity in neurons of the medial prefrontal cortex through basolateral amygdala inputs”, Journal of Neuroscience, 2006,26:6458–6468 Leweke F., Koethe D., Gerth C., Nolden B.M., MaussC., Schrelber D., Hansel A., Neatby M.A., Jeulicher A. y KlosterKotter J., “Cannabidiol as an anti-psychotic: a double-blind, controlled clinical trial of cannabidiol versus amisulpiride in acute schizophrenia”, 15th annual symposium on cannabinoids, Clearwater Beach, FL: Cannabinoid Research Society, 2005, Abstract. Lewis, D.A.y levit P. Schizophrenia as ea disorder of neurodevelopment.Annual Review of neuroscience, 2002. 25, 409-432 Lisman J.E., Coyle J,T, Green R.W., Javitt D.C., Bees F.M., Heckers S., Circuit based framework fror understanding neurotransmitter and risk gene interactions in schizophrenia, Trend Neurosci. 2008; 31 (5). 234-242 Malone D.T., Hill M.N. y Rubino T., “Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models”, Br J Psicopharmacol, 2010, 1160: 511-22. Marsicano G., Goodenough S., Monory K., Hermann H., Eder M., Cannich A., Azad S.C., Cascio M.G., Gutierrez S.O., van der Stelt M., Lopez-Rodriguez M.L., Casanova E., Schutz G., Zieglgansberger W., Di Marzo V., Behl C. y Lutz B., “CB1 cannabinoid receptors and on-demand defense against excitotoxicity”,Science, 2003, 302:84–88. Mato S. Del Olmo E y Pazos A., “Ontogenetic development of cannabinoid receptor expression and signal transduction functionality in the human brain”, Eur Journal Neuroscience, 2003, 17:1747–1754. Meschler J.P. y Howlett A.C. “Signal transduction interactions between CB1 cannabinoid and dopamine receptors in the rat and monkey striatum”, Neuropharmacology, 2001, 40:918–926. Misner D.L. y Sullivan J.M., “Mechanism of cannabinoid effects on long-term potentiation and depression in hippocampal CA1 neurons”, Journal of Neuroscience, 1999, 19:6795–6805 Moore T.H.M., Zammit S., Lingford-Hughes A., Baenes T.R.E., Jones P.B., Burke M. y Lewis G., “Cannabis Use and risk of psychotic or affective mental health outcomes: a systematic review”, The Lancet , 2007, vol 370:319-328. Mulder J, Aguado T, Keimpema E, Barabas K, Ballester Rosado CJ, Nguyen L, et al. Endocannabinoid signaling controls pyramidal cell specification and long-range axon patterning. Proc Natl Acad Sci U S A. 2008;105:8760–8765 Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365:61–65. Okubo Y., Suhara T., Sudo Y. y Toru M., “Possible role of dopamine D1 receptors in schizophrenia”, Mol Psychiatry, 1997, 2:291–292. O’Tuathaigh C.M., Hryniewiecka M., Behan A., Tighe O, et al., “Chronic adolescent exposure to delta-9-tetrahydrocannabinol in COMTknockout mice: impact on phenotypes relevant to psychosis”, Neuropsychopharmacology, 2010c, 35, 2262– 2273. O'Tuathaigh C.M., Clarke G., Walsh J., Desbonnet L., Petit E., O'Leary C., Tighe O, Clarke N., Karayiorgou M., Gogos J.A., Dinan T.G., Cryan J.F. y Waddington J.L., “Genetic versus. Pharmacological Inactivation of COMT Influences Cannabinoid-Induced Expression of Schizophrenia- Related Phenotypes”, I. J Neuropsychopharmacol, octubre de 2012; 15 (9); 1331-42. Papaleo R., “Alteración de la memoria de trabajo en la esquizofrenia”, Sicofarmacología 2011, 70: 19-29. Pelayo-Teran J.M., Perez-Iglesias R., Mata I., Carrasco-Marin E., Vázquez-Barquero J.L. y Crespo- Facorro B., “Catechol-Omethyltransferase(COMT) Val158Met variations and cannabis use in firstepisode non-affective psychosis:clinical-onset implications”, Psychiatry Research; 2010, 179: 291-296. Pelayo-Teran, J.M., Crespo-Facorro, B., Carrasco- Marin, E., Perez-Iglesias, R., Mata, I., Arranz, M.J., Leyva-Cobian, F. y Vazquez-Barquero, J.L., “Catechol-O-methyltransferaseVal158Met polymorphism and clinical characteristics in first episode non-affective psychosis. American Journal of Medical Genetics”, Part b, Neuropsychiatric Genetics, 2008a, 147B, 550–556. Pertwee R.G., “Pharmacology of cannabinoid CB1 and CB2 receptors”, Pharmacol Ther, 1997, 74:129–180 Piomelli D, Beltramo M, Giuffrida A y Stella N., “Endogenous cannabinoid signaling”, Neurobiol Dis., 1998, 5:462–473. Pistis M., Ferraro L., Pira L., Flore G., Tanganelli S., Gessa G.L. y Devoto P., “Delta(9)-tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: an in vivo microdialysis study”, Brain Res., 2002,948:155–158. Robbe D, Alonso G, Duchamp F, Bockaert J y Manzoni O.J., “Localization and mechanisms of action of cannabinoid receptors at the glutamatergic synapses of the mouse nucleus accumbens”, Journal of Neuroscience, 2001, 21:109–116. Roussos P., Giakoumaki S.G. y Bitsios P., “Tolcapone Effects on Gating, Working Memory, and Mood interact with Synonymous Catechol-O- Methyltransferasers4818c/g Polymorphism”, Biological Psychiatry, 2009, 66, 997-1004. Schweinsburg A.D., Schweinsburg B.C., Medina K.L., McQueeny T., Brown S.A. y Tapert S.F., “The influence of regency of use on fMRI reponse during spatial working memory in adolescent marijuana users” J. Psycoactive Drugs, 2010, 42(3): 401- 412 Sneider J.T., Poper H.G., Jr Silveri M.M., Simpson N.S., Gruber S.A. y Yurgelun-Todd D.A.,”Differences in regional Blood volume during 28-day period of abstinence in cronic cannabis smokers”; Eur Nueropsycopharmacol, 2008, 18: 612-619 Steafesson H., Sarginson J., Kong A., Yates P., Steinthorsdottir V., Gudfinnsson E., Gunnarsdottir S., Walker N., Petursson H., Crombie C., Ingarson A., Gulcher J.R., Steafensson K. y St Clair D., “Association of neuregulin 1 with schizophrenia confirmed in a Scottish population”, Am J Hum Genet, 2003, 72 (1): 83-7 Sullivan J.M., “Mechanisms of cannabinoid-receptor-mediated inhibition of synaptic transmission in cultured hippocampal pyramidal neurons”, M.J: Neurophysiol., 1999, 82:1286–1294 Van Os j.; Bak M.; Hanse M.; Bijl RV.; de Graaf R.; Verdoux H.; Cannabis use and psychosis: a longitudinal population-based Study. Am J Epidemiol. (2002); 156:319-327 Wang X.J., y Buzsaki G., “Gamma oscillation by synaptic inhibition in a hippocampal interneuronal network model”, J. Neuroscience, 1996, 16:6402– 6413. Wilson R.I. y Nicoll RA., “Endocannabinoid signaling in the brain”, Science, 2002, 296:678–682. Wobrock T., Hasan A.;Malchow B., Wolff-Menzler C., Guse B., Lang N., Schneider-Axmann T., Ecker U.K.H. y Falkai P., “Increased Cortical Inhibition Deficits in First-Episode Schizophrenia with Comorbid Cannabis Abuse”, Psychopharmacology (Berl); febrero de 2010, 208(3): 353–363. Zammit S.; Allebeck P.; Andreason S; Lundberg I.; Lewis G.; Self-reported cannabis use as a risk factor for schizophrenia: further analisis of the 1969 Suedish conscript cohort; BJM; (2002); 325: 1199-1202 Zieher L.M. y Brio M.C., Tratado de psiconeurofarmacología y Neurociencia; Esquizofrenia y otras psicosis. Neurobiología y terapéuticas, editorial Sciens, 2009, vol 1. Zieher L.M., “Aspectos neurobiológicos de la esquizofrenia”, Psicofarmacología 25, 2004, 17- 22. Zieher L.M., “Circuitos Neurotrasmisores y genes de riesgo en la esquizofrenia”, Psicofarmacología, 2008, 52: 8-13. Zuardi A.W., Hallak J.E., Dursun S.M., Morais S.L., Sanches R.F., Musty R.E. y Crippa J.A., “Cannabidiol monotherapy for treatment-resistant schizophrenia”, Journal of Psychopharmacology, 2006,20:683–686. 18 // EDITORIAL SCIENS

Biblioteca

Av. García del Río 2585 Piso 12 A - C.A.B.A
+54 11 2092 1646 | info@sciens.com.ar

Editorial Sciens, Todos los Derechos Reservados 2015